SpectraCure has registered the trademark Q-PRO[®]
SpectraCure AB (publ) has obtained trademark protection for Q-PRO[®], the name of the new generation system, in Europe and in the USA. Applications to register the trademark have been submitted in Australia, China and Japan. SpectraCure is developing a system for treatment of recurrent prostate cancer. The system is currently used in a clinical study […]
SpectraCure’s new treatment system has been approved in the UK for use in clinical trials
SpectraCure's new generation of treatment systems has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) for use in the ongoing clinical trial for the treatment of relapsing prostate cancer. The new treatment system has already been approved by the authorities in Canada and the USA, which means that the system is now approved […]
Patent regarding the new generation of treatment systems approved in Europe
SpectraCure's patent application relating to the technical solution in the new generation of treatment systems has been approved by the European Patent Office. The patent describes the technical solution that allows SpectraCure's treatment system to use the same optical fibers (light guide) to deliver the treatment light and to perform the measurements, to enable individual […]
SpectraCure’s CEO is leaving the company
Johan Folkunger has today informed the board that he is resigning from his position as CEO of SpectraCure. Johan Folkunger is leaving SpectraCure as a result of being offered, and having accepted, a new assignment as CEO of another company. Johan Folkunger has a notice period of six months and will continue to work during […]
Software for improved imaging technology is approved for use in clinical study in the US
MedCom GmbH's medical imaging technology, which has been integrated with SpectraCure's IDOSE[®] system, is approved by the Food and Drug Administration (FDA) for use in the clinical study in the US. The integration makes the treatment more efficient and facilitates the process. In December 2021 a development project, partially funded by EU, was completed together […]
SpectraCure has been approved a grant from EU of € 125,000
SpectraCure has been approved a grant from EU of € 125,000 for an industrialization project for the company's product, for the treatment of prostate cancer with interstitial photodynamic treatment (PDT). The grant is approved as part of MedPhab, a so-called "pilot production line", financed through grants from the EU's Horizon 2020 program. In the project, […]
Patent approved in Europe
SpectraCure's patent application for a new technology, to improve the company's IDOSE® technology, has been approved by the European Patent Office, EPO. The IDOSE® technology is central to SpectraCure's method of treating prostate cancer with photodynamic tumor therapy (PDT). In short, IDOSE® technology means that the prostate tissue is monitored during treatment with a series […]
Status update on clinical trial for the treatment of relapsed prostate cancer patients
The pandemic has led to a significant slowdown in SpectraCure's clinical activities. Several hospitals suspended the conduct of studies for an extended period of time and SpectraCure staff have been prevented from travelling due to travel bans in the countries where the study is being conducted. The clinical study protocol involves a number of follow-up […]
SpectraCure AB publishes Quarterly Report 1, 2021
First quarter 2021 Figures for 2021 and 2020 refer to the Group. Other operating income amounted to KSEK 1,597 (1,185) Result after taxes amounted to KSEK -4,773 (-3,784) Basic and diluted earnings per share: SEK -0.05 (-0.04) Cash flow for the period amounted to KSEK -4,309 (-3,624) Solidity: 92 (86)% […]
The Nomination Committee’s proposal for election of board members in SpectraCure AB
The Nomination Committee has decided to propose the re-election of Board members Ingemar Kihlström, Katarina Svanberg, Sune Svanberg, Ulf Bladin and Hans Bornemark at the Annual General Meeting of SpectraCure AB (publ) on Tuesday 18 May 2021. Ingemar Kihlström is proposed for re-election as Chairman of the Board. Masoud Khayyami, current Board Member, has declined […]
